Roche Holding AG Virtual Neurology Investor Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Richard Parkes - BNP Paribas Exane - Analyst : Yes, just a couple of questions. First one is more of a sort of thought experiment. It's just about the one thing that I kind of worry about when you're thinking about the risk of ARIA with a brainshuttle antibody. And I'm just thinking, is there -- I'm thinking if there's a risk that we might see a lower instance of incidental ARIA findings, but a higher frequency of more severe events given the deep brain penetration of the product? So I'm just wondering, is there anything that might link to the patient that died with effects that might implicate that? And what's your thinking about that risk? And is there a biological reason why I should worry about that less? And then the second question is on the Phase III design and the time lines that you outlined because obviously, the FDA now will accept beta amyloid reduction as a surrogate endpoint. Can you talk about how you might factor that into the trial design? And does the 2028 readout assume demonstration of clinical outcomes? Or is there potential for an interim to accelerate that?